Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Free Report) was the target of a significant growth in short interest in June. As of June 15th, there was short interest totalling 9,900 shares, a growth of 54.7% from the May 31st total of 6,400 shares. Approximately 0.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 32,700 shares, the days-to-cover ratio is presently 0.3 days.
Tenax Therapeutics Stock Up 1.0 %
Tenax Therapeutics stock opened at $3.01 on Monday. The company has a fifty day simple moving average of $3.45 and a 200-day simple moving average of $7.20. Tenax Therapeutics has a 52-week low of $2.77 and a 52-week high of $61.20.
Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last announced its quarterly earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($3.12) earnings per share for the quarter, missing the consensus estimate of ($2.40) by ($0.72). Equities analysts anticipate that Tenax Therapeutics will post -7.96 EPS for the current fiscal year.
Wall Street Analyst Weigh In
View Our Latest Analysis on TENX
Tenax Therapeutics Company Profile
Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Further Reading
- Five stocks we like better than Tenax Therapeutics
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- 3 Recent Stock Buybacks: Adobe, Marathon, and FedEx Lead the Way
- 3 REITs to Buy and Hold for the Long Term
- 3 Stocks Upgraded by Analysts: Home Depot, U.S. Steel, Alcoa
- Breakout Stocks: What They Are and How to Identify Them
- NVIDIA and TSM Stock: Is Semiconductor Sector Momentum Slowing?
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.